Mobile

A phase II, open-label, randomized, multicentre study to evaluate the feasibility of GSK Biologicals’ DTPa-IPV/Hib-MenC-TT vaccine co-administered with Prevenar compared with Pediacel co-administered ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-003741-87

A phase II, open-label, randomized, multicentre study to evaluate the feasibility of GSK Biologicals’ DTPa-IPV/Hib-MenC-TT vaccine co-administered with Prevenar compared with Pediacel co-administered with Menjugate and Prevenar, when given in healthy infants as a three-dose primary vaccination course at 2, 3 and 4 months of age and to evaluate Menitorix given to these children as a booster dose at 12 months of age

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

•To demonstrate that GSK Biologicals’ DTPa IPV/Hib-MenC-TT vaccine co-administered with Prevenar (MenC-Combo group) is non-inferior to Pediacel co-administered with Prevenar and Menjugate (Control group), in terms of immune response to Hib and MenC, one month after the third dose of primary vaccination. Criteria for non-inferiority: Non-inferiority in terms of response to PRP will be demonstrated if the upper limit of the 95% confidence interval (CI) on the group difference (Control minus MenC-Combo group) in percentage of subjects with anti-PRP concentrations >= 0.15 micrograms/ml is <=10%. Non-inferiority in terms of response to MenC will be demonstrated if the upper limit of the 95% CI on the group difference (Control minus MenC-Combo group) in percentage of subjects with SBA-MenC titres >= 8 is <=10%.

Critère d'inclusion

  • Primary immunisation of healthy infants in the first year of life against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b (Hib), serogroup C meningococcal and Streptococcus pneumoniae diseases. Booster immunisation of healthy one-year-old children against Hib and serogroup C meningococcal diseases

Liens